» Articles » PMID: 27457520

Estrogen Receptor α Promotes Breast Cancer by Reprogramming Choline Metabolism

Overview
Journal Cancer Res
Specialty Oncology
Date 2016 Jul 27
PMID 27457520
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Estrogen receptor α (ERα) is a key regulator of breast growth and breast cancer development. Here, we report how ERα impacts these processes by reprogramming metabolism in malignant breast cells. We employed an integrated approach, combining genome-wide mapping of chromatin-bound ERα with estrogen-induced transcript and metabolic profiling, to demonstrate that ERα reprograms metabolism upon estrogen stimulation, including changes in aerobic glycolysis, nucleotide and amino acid synthesis, and choline (Cho) metabolism. Cho phosphotransferase CHPT1, identified as a direct ERα-regulated gene, was required for estrogen-induced effects on Cho metabolism, including increased phosphatidylcholine synthesis. CHPT1 silencing inhibited anchorage-independent growth and cell proliferation, also suppressing early-stage metastasis of tamoxifen-resistant breast cancer cells in a zebrafish xenograft model. Our results showed that ERα promotes metabolic alterations in breast cancer cells mediated by its target CHPT1, which this study implicates as a candidate therapeutic target. Cancer Res; 76(19); 5634-46. ©2016 AACR.

Citing Articles

ZNF32 histidine 179 and 183 single-site and double-site mutations promote nuclear speckle formation but differentially regulate the proliferation of breast cancer cells.

Zhong C, Chen D, Wang F, Wang J, Li R, Li Y Front Cell Dev Biol. 2025; 13:1490231.

PMID: 40046230 PMC: 11880268. DOI: 10.3389/fcell.2025.1490231.


In Silico Design of Dual Estrogen Receptor and Hsp90 Inhibitors for ER-Positive Breast Cancer Through a Mixed Ligand/Structure-Based Approach.

La Monica G, Alamia F, Bono A, Mingoia F, Martorana A, Lauria A Molecules. 2025; 29(24.

PMID: 39770128 PMC: 11676166. DOI: 10.3390/molecules29246040.


Prognostic significance of total choline on in-vivo proton MR spectroscopy for prediction of late recurrence in patients with hormone receptor-positive, HER2-negative early breast cancer.

Kim H, Park H, Chun Y, Kim H, Baek H, Kim Y PLoS One. 2025; 20(1):e0311012.

PMID: 39746051 PMC: 11695009. DOI: 10.1371/journal.pone.0311012.


Clinical measures in chronic neuropathic pain are related to the Kennedy and endocannabinoid pathways.

Bourke S, Suarez E, Islam B, Stephenson J, Finn D, McHugh P Eur J Clin Invest. 2024; 55(2):e14351.

PMID: 39545479 PMC: 11744925. DOI: 10.1111/eci.14351.


Mitochondrial-related genes as prognostic and metastatic markers in breast cancer: insights from comprehensive analysis and clinical models.

Fang Y, Zhang Q, Guo C, Zheng R, Liu B, Zhang Y Front Immunol. 2024; 15:1461489.

PMID: 39380996 PMC: 11458410. DOI: 10.3389/fimmu.2024.1461489.